The FDA has given the green light to Lumvoa, a groundbreaking drug for thyroid eye disease (TED), marking a significant milestone in treatment options. Lumvoa, developed by Viridian Therapeutics, is the first therapeutic solution to demonstrate statistically significant improvements in both the diplopia response and complete resolution of diplopia across active and chronic stages of TED. This disease can severely impact vision and quality of life, presenting with a range of symptoms due to autoimmune-driven inflammation followed by chronic tissue fibrosis.
Lumvoa received priority review approval following successful Phase III clinical trials, THRIVE and THRIVE-2, which showed remarkable improvements at week 15 in all major symptoms of TED. Patients undergoing a 12-week Lumvoa treatment, consisting of five intravenous infusions, experienced notable reductions in proptosis as early as three weeks into the therapy, alongside enhanced quality of life. With plans for immediate launch, Lumvoa will soon be available for prescription, supported by efforts to ensure broad access through collaboration with payers and healthcare providers.
